Emapalumab Therapy for Hemophagocytic Lymphohistiocytosis Before Reduced-Intensity Transplantation Improves Chimerism

Research Report on Pre-HCT Emapalumab Therapy Improving Donor Chimerism in Children with HLH Background and Objective of the Study Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune disorder caused by pathological immune activation. The primary mechanism involves the functional deficiency of cytotoxic activity in natural killer (...

Prognostic Impact of Cytogenetic Abnormalities Detected by FISH in AL Amyloidosis with Daratumumab-Based Frontline Therapy

Review of the Impact of FISH-Detected Cytogenetic Abnormalities on Prognosis in AL Amyloidosis in the Era of Daratumumab Therapy Background Immunoglobulin light chain (AL) amyloidosis is a rare disease characterized by organ dysfunction caused by the deposition of light chain proteins secreted by abnormal plasma cells. However, the heterogeneous cl...

Classical Pathway Stimulus in Complement-Mediated Thrombotic Microangiopathy

Utilizing Complement Biosensors to Explore Novel Mechanisms in Complement-Mediated Thrombotic Microangiopathy Background and Necessity Complement-mediated thrombotic microangiopathy (CM-TMA) is a thrombotic microangiopathy caused by complement system dysregulation, with complex clinical manifestations including subtypes such as atypical hemolytic u...

Rates of Strokes in Californians with Sickle Cell Disease in the Post-STOP Era

Changes in Stroke Incidence in Californians with Sickle Cell Disease: A Population-Based Study in the Context of the STOP Trial Background and Objective Sickle Cell Disease (SCD) is a hereditary blood disorder characterized by abnormal hemoglobin, causing red blood cells to deform into a sickle shape under low-oxygen conditions. This deformation in...

Follicular Lymphoma Comprises Germinal Center–Like and Memory-Like Molecular Subtypes with Prognostic Significance

Progress in Molecular Classification of Follicular Lymphoma: A Dual Typing Predictive Model Based on RNA Sequencing and Immunohistochemistry Follicular Lymphoma (FL) is a B-cell malignancy characterized by a slow clinical progression, with a median overall survival extending up to 20 years. However, the heterogeneous nature of FL leads to significa...

Recurrent CLTC::SYK Fusions and CSF1R Mutations in Juvenile Xanthogranuloma of Soft Tissue

Research on Juvenile Xanthogranuloma Reveals Novel Genetic Mutations Juvenile xanthogranuloma (JXG), a rare histiocytic neoplasm, typically manifests in the skin but occasionally presents extracutaneously in locations such as soft tissue or the central nervous system (CNS). The genetic drivers underlying these extracutaneous variants remain poorly ...

RBM39 as a Therapeutic Target in Acute Lymphoblastic Leukemia: Disruption of Cotranscriptional Splicing

Research Summary Potential of Targeting RBM39 in High-Risk Acute Lymphoblastic Leukemia (B-ALL) Background Overview Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy commonly diagnosed in children and young adults. Despite high remission rates through frontline chemotherapies, the long-term survival rate for patients with relapsed/re...

Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations

Report on the Academic Paper: Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations Academic Background and Research Motivation Telomere biology disorders (TBDs) are a group of diseases caused by pathogenic germline variants (PGVs) in telomere-related genes, manifesting with multi-organ dysfunctio...

Ide-cel vs Standard Regimens in Triple-Class–Exposed Relapsed and Refractory Multiple Myeloma: Updated KARMMA-3 Analyses

Latest Research Report: Idecabtagene Vicleucel (ide-cel) Significantly Extends Progression-Free Survival in Triple-Class Exposed (TCE) Relapsed or Refractory Multiple Myeloma – Results from the KARMMA-3 Clinical Trial Academic Background and Research Question Patients with Multiple Myeloma (MM) often relapse after multiple lines of therapy, with pr...

Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...